<SEC-DOCUMENT>0001102624-13-000803.txt : 20130711
<SEC-HEADER>0001102624-13-000803.hdr.sgml : 20130711
<ACCEPTANCE-DATETIME>20130711080911
ACCESSION NUMBER:		0001102624-13-000803
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130711
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130711
DATE AS OF CHANGE:		20130711

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		13962959

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: July      11, 2013</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>ME</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>207-878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 8.01. Other Events</b></b><br>
<br>
FIRST DEFENSE(R) IS NOW OMRI LISTED AND MAY BE USED WITH CERTIFIED ORGANIC DAIRY AND BEEF CATTLE
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br />
<br>

<p>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated July      11, 2013</a></b>
<br>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table border="0" width="100%">
<tr>
<td width="50%" valign=top>
Dated: July      11, 2013<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President & CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated July      11, 2013</td>
</tr>
</table>
</center>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>

<p></p>
<b>First Defense(R) Is Now OMRI Listed and May Be Used With Certified Organic Dairy and Beef Cattle </b>
<p>PORTLAND, ME -- (Marketwired - July      11, 2013) -  <b>ImmuCell Corporation </b>(NASDAQ: ICCC) today announced that <b>First Defense</b>&#174;, a USDA-approved scours preventative for newborn dairy and beef calves, has been reviewed by the Organic Materials Review Institute (OMRI) and has been listed with products eligible for use in certified organic production, subject to approval by USDA accredited certifiers.
</p>
<p>
The USDA recently approved a label change for the <b>First Defense</b>&#174; packaging that permits the OMRI logo to be printed on the box. The OMRI logo is displayed at the top of this press release.
</p>
<p>
"<b>First Defense</b>&#174; has one of the strongest efficacy claims available from the USDA -- proven to reduce mortality and morbidity associated with E. coli and coronavirus," says Bobbi Jo Brockmann, Director of Sales and Marketing for ImmuCell Corporation. "Now these benefits can also improve calf health on organic dairy and beef operations, protecting calves when they need it most -- immediately following birth."
</p>
<p>
<b>First Defense</b>&#174; has been approved for use in conventional production since 1991. The product is produced from hyper-immunized bovine colostrum and is available for oral delivery in a bolus. These highly specific antibodies work to reduce scours outbreaks by preventing E. coli and coronavirus infections.
</p>
<p>
For maximum protection, <b>First Defense</b>&#174; should be provided to calves within the first 12 hours after birth without a requirement to delay colostrum feeding. The product provides protective levels of antibodies to potential sites of infection, delivering preformed immunity and immediate protection to calves so they can reach their genetic potential.
</p>
<p>
"There are not many disease prevention tools on the market that are okay for organic producers to use, so <b>First Defense</b>&#174; being OMRI listed is big news in our industry," says Kyle Sharp, owner/operator of Sharp Family Dairy in Amanda, Ohio. "This notification means we can focus on disease prevention in our calves from the start. Having another tool in our toolbox, especially one that helps prevent disease -- is very valuable."
</p>
<p>
<b>First Defense</b>&#174; was permitted for use in organic production as part of the 2013 OMRI Products List. OMRI is recognized by USDA accredited certifiers as being able to accurately review input products against the National Organic Program Rule standards and to provide recommendations to organic certifiers, growers, manufacturers and suppliers on products intended for use in certified organic production, handling and processing. To view the OMRI list of approved products visit www.omri.org.
</p>
<p>
For more information on how <b>First Defense</b>&#174; provides calves with immediate immunity, like Immediate Immunity&#8482; on Facebook at www.facebook.com/ImmediateImmunity, view the Immediate Immunity&#8482; YouTube channel at www.youtube.com/ImmediateImmunity, or visit www.ImmediateImmunity.com.
</p>
<p>
About ImmuCell:<br>
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, (http&#58;//www.immucell.com).

</p>
<pre>
<b>Contact:
</b>Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
